New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export NVO’s income statement to Excel — free account
Novo Nordisk A/S
NVOHealthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +3.87%
- EPS
- −17.1%
- Free cash flow
- −14.8%
- Total debt
- +30.7%
Quarter to September 2026, against a year earlier
38.57
0.32
−0.82%
Follow NVO
Alert me
Revenue to profit Q3 FY2026, quarter to Sep 30, 2026
Of every $100 of revenue, $20.23 was left as profit. Gross margin has fallen two quarters running, from 86.0% to 77.0%. What is an income statement?
| Revenue | 12.2 | 100.0% |
|---|---|---|
| Cost of revenue | −2.8 | −23.0% |
| Gross profit | 9.4 | 77.0% |
| Research & development | −3.1 | −25.1% |
| Selling, general & admin | −2.5 | −20.5% |
| Other operating costs | −0.3 | −2.3% |
| Operating income | 3.5 | 29.1% |
| Other income, net | −0.2 | −2.0% |
| Income tax | −0.7 | −5.9% |
| Other items | −0.1 | −0.9% |
| Net income | 2.5 | 20.2% |
Net margin (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | $12.3B | $15.2B | $12.2B | $12.2B |
| Operating income | $5.1B | $9.3B | $4.2B | $3.5B |
| Net income | $3.7B | $7.6B | $3.2B | $2.5B |
| Net margin (right axis) | 29.8% | 50.2% | 26.3% | 20.2% |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Revenue |
12,196.03 | 12,212.73 | 15,162.48 | 12,343.02 |
+8 more quarters Free account |
Revenue Growth |
3.87% | 4.47% | 37.61% | 0.67% | |
Cost of Revenue |
2,808.50 | 2,660.76 | 2,129.45 | 2,324.08 | |
Gross Profit |
9,387.53 | 9,551.97 | 13,033.04 | 10,018.94 | |
R&D Expenses |
3,065.06 | 2,767.66 | 1,610.47 | 2,235.65 | |
SG&A Expenses |
2,503.42 | 2,537.21 | 2,069.78 | 2,699.90 | |
Operating Income |
3,543.69 | 4,210.69 | 9,336.18 | 5,057.82 | |
Non-operating Interest Expenses |
174.64 | 233.40 | 547.94 | (219.96) | |
Non-operating Income/Expense |
(242.86) | (28.94) | 399.96 | 342.88 | |
| 3,300.84 | 4,181.75 | 9,736.14 | 5,400.70 | ||
Income Tax Provision |
722.88 | 915.86 | 2,132.11 | 1,152.93 | |
Income after Tax |
2,577.96 | 3,265.89 | 7,604.03 | 4,247.77 | |
Net Income Common |
2,577.96 | 3,265.89 | 7,604.03 | 4,247.77 | |
EPS (Basic) |
0.58 | 0.74 | 1.71 | 0.94 | |
EPS (Diluted) |
0.58 | 0.74 | 1.71 | 0.94 | |
Shares (Basic, Weighted) |
4,405.26 | 4,435.80 | 4,441.60 | 4,443.00 | |
Shares (Diluted, Weighted) |
4,416.58 | 4,435.80 | 4,449.40 | 4,447.70 | |
Gross Margin |
76.97% | 78.21% | 85.96% | 81.17% | |
EBIT Margin |
29.06% | 34.48% | 61.57% | 40.98% | |
EBT margin |
27.06% | 34.24% | 64.21% | 43.76% | |
Net Profit Margin |
21.14% | 26.74% | 50.15% | 34.41% | |
EBITDA |
5,734.84 | 5,810.46 | 9,889.92 | 5,814.52 | |
EBIT |
3,543.69 | 4,210.69 | 9,336.18 | 5,057.82 | |
Income from Continuous Operations |
2,577.96 | 3,265.89 | 7,604.03 | 4,247.77 | |
Consolidated Net Income/Loss |
2,577.96 | 3,265.89 | 7,604.03 | 4,247.77 | |
EPS (Basic, from Continuous Ops) |
0.59 | 0.74 | 1.71 | 0.96 | |
EPS (Diluted, from Cont. Ops) |
0.58 | 0.74 | 1.71 | 0.95 | |
EPS (Basic, Consolidated) |
0.59 | 0.74 | 1.71 | 0.96 | |
EPS (Diluted, Consolidated) |
0.58 | 0.74 | 1.71 | 0.95 | |
Shares (Diluted, Average) |
4,416.89 | 4,435.80 | 4,442.54 | 4,449.40 | |
EBITDA Margin |
47.02% | 47.58% | 65.23% | 47.11% | |
Operating Cash Flow Margin |
51.63% | 70.13% | 24.87% | 4.65% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026